Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levetiracetam as a Sensitizer of Temozolomide in Newly Diagnosed Glioblastoma
NCT02815410Phase 2Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Jul 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of levetiracetam in glioblastoma (GBM), sponsored by Seoul National University Hospital. Primary endpoint: 6 months Progression Free Survival. Status: unknown.
02
Drugs
levetiracetam
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02815410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02815410.